

WMS 2023 Summary Programme

Monday 2 nd October 2023	
08:30-19:00	Pre-Congress Teaching Course (separate registration required)

Tuesday 3 rd October 2023	
08:00-11:00	Pre-Congress Teaching Course (separate registration required)
11:00-16:00	WMS Executive Board Meeting 📍 Meeting Room
15:30-18:00	Registration 📍 Ballroom Foyer, refreshments 📍 PAC Foyer and Exhibit Hall and poster set up 📍 Ballroom Foyer
16:30-17:30	Industry Symposium 1 📍 PAC Industry Symposium 2 📍 Exhibit Hall A1
18:00-18:45	Opening Ceremony 📍 PAC INV01: The strength to explore: a review of NASA experience with muscle atrophy in space <i>Don Thomas, Ohio Astronaut, USA</i> <i>Moderators: Lindsay Alfano & Chris Wehl</i>
18:45-21:00	Networking Reception 📍 Congress Venue (separate registration required)

Wednesday 4 th October 2023	
06:30-19:30	Registration desk open
07:30-08:30	Industry Symposium 3 📍 PAC Industry Symposium 4 📍 Exhibit Hall A1
09:00-09:15	Congress Welcome 📍 PAC Message from the President
09:15-10:45	📍 PAC Topic 1: Understanding phenotypic and genetic diversity in neuromuscular disorders 1 <i>Moderators: Gina Ravenscroft, University of Western Australia, Australia & Marco Savarese, University of Helsinki, Finland</i> 09:15-09:45 INV02: High throughput functional assays to improve interpretation of rare variants discovered in Neuromuscular disease genes <i>Monkol Lek, Yale School of Medicine, USA</i> 09:45-10:15 INV03: Understanding genetic variants in neuromuscular disorders <i>Chris Wehl, Washington University in St. Louis, USA</i>



	<p>10:15-10:30 O01: Clinical spectrum and molecular features of asymptomatic and paucisymptomatic DMD mutations <i>Stefan Nicolau, Nationwide Children's Hospital, USA</i></p> <p>10:30-10:45 O02: Unpacking gene expression profile to the single nuclei level in human muscle Pompe samples <i>Jordi Diaz-Manera, Newcastle University, UK</i></p>		
10:45-11:15	Morning refreshments & exhibition 📍 Exhibit Hall and posters 📍 Ballroom		
10:45-11:15	Social Media Committee find out about how to get involved 📍 Myology Café, Exhibit Hall		
11:15-13:15	<p>📍 PAC</p> <p>Topic 1: Understanding phenotypic and genetic diversity in neuromuscular disorders 2</p> <p><i>Moderators: Gisèle Bonne, Centre de Recherche en Myologie, France & Charlotte Lilien, MDUK Oxford Neuromuscular Centre, UK</i></p> <p>11:15-11:45 INV04: Accounting for phenotypic variability in clinical outcome assessments <i>Lindsay Alfano, Nationwide Children's Hospital, USA</i></p> <p>11:45-12:15 INV05: Engaging patients from diverse backgrounds in NMD research <i>Gita Ramdharry, UCL Queen Square, Institute of Neurology, UK</i></p> <p>12:15-12:30 O03: In vivo gene therapy for striated muscle laminopathy <i>Mariko Okubo, Institut de Myologie, France</i></p> <p>12:30-12:45 O04: Myoguide.org: a web-based portal supporting the analysis of MRIs for the diagnosis of neuromuscular patients <i>Carla Bolaño Diaz, John Walton Muscular Research Centre, UK</i></p> <p>12:45-13:00 O05: TDP-43 dependent cryptic exon derived neopeptides as a novel diagnostic biomarker in muscle biopsies of inclusion body myositis patients <i>Chiseko Ikenaga, Johns Hopkins University School Of Medicine, USA</i></p> <p>13:00-13:15 O06: Clinical trial readiness and validation of onsite and remote evaluation in valosin containing protein-associated multisystem proteinopathy: A 24-month longitudinal study <i>Natalie Reash, Nationwide Children's Hospital, USA</i></p>		
13:15-14:30	Lunch & exhibition 📍 Exhibit Hall and posters 📍 Ballroom		
13:45-14:15	New WMS Members Event 📍 Myology Café, Exhibit Hall		
14:30-15:30	Poster session 1 📍 Ballroom A-C <i>Refreshments served</i>		
	<p>P41-P42, VP43, P44-P47, VP48, P49-P54, VP55: Clinical trial highlights</p> <p>P56-P57, P59-P67: Therapies for neuromuscular disorders</p> <p>VP114-VP116, P117, VP118-VP119, P120-P126 Muscle MRI</p> <p>P127-P151: DMD - imaging and outcome measures</p> <p>P205-P212, VP213, P214-P215, VP216, P217-P225, VP226, P227, VP228, P229-P234 SMA - clinical</p> <p>P319-P333, VP334, P335-P338, VP339, P340: Myositis</p>		
15:30-16:00	<p>Short Oral Presentations 1</p> <p>📍 Ballroom C1</p> <p>P319-P322, P126-P127</p> <p><i>Moderator: Tahseen Mozaffar, University of California, USA</i></p>	<p>Short Oral Presentations 2</p> <p>📍 Ballroom C2</p> <p>P205-210</p> <p><i>Moderator: Laurent Servais, University of Oxford, UK</i></p>	<p>Short Oral Presentations 3</p> <p>📍 Ballroom C3</p> <p>P211-P212, P56, P57, P59</p> <p><i>Moderator: Jana Haberlová, Motol University Hospital, Czech Republic</i></p>



16:15-17:00	<p>📍 PAC</p> <p>Debate: Is the muscle biopsy still indicated? <i>Moderators: Teerin Liewluck, Mayo Clinic-Rochester, USA & Edoardo Malfatti, Paris Est University/INSERM U955, France</i></p> <p>INV06: <i>Teresinha Evangelista, Institut de Myologie, France</i></p> <p>INV07: <i>Baziel van Engelen, Radboud University Medical Centre, The Netherlands</i></p>		
17:15-18:15	<p>Poster session 2 📍 Ballroom A-C <i>Refreshments served</i></p>		
	<p>P12-P18, P20-P37, VP38, P39-P40: DMD - treatments</p> <p>P168-P177, VP178, P179-P187, VP188, P189-P190: Genetics of neuromuscular disorders</p> <p>P281-P285, VP286, P287-P288, VP289, P290, VP291, P292-P305, VP306, P307: Limb-girdle muscular dystrophies</p> <p>P308-P316, VP317, P318: Facioscapulohumeral muscular dystrophy</p> <p>P398-P413, VP414, P415, VP416-VP417, P418-P420: Congenital myopathies</p>		
18:15-18:45	<p>Short Oral Presentations 4 📍 Ballroom C1 P398-P403 <i>Moderator: Anna Sarkozy, Dubowitz Neuromuscular Centre, Great Ormond Street Hospital, UK</i></p>	<p>Short Oral Presentations 5 📍 Ballroom C2 P168, P281-P285 <i>Moderator: Meredith James, John Walton Muscular Dystrophy Research Centre, UK</i></p>	<p>Short Oral Presentations 6 📍 Ballroom C3 P169-P172, P308-P309 <i>Moderator: Vishnu Venugopalan Thampy Yamuna, All India Institute of Medical Sciences, India</i></p>
19:15-20:15	<p>Industry Symposium 5 📍 PAC</p>		<p>Industry Symposium 6 📍 Exhibit Hall A1</p>

Thursday 5th October 2023

07:00-15:00	<p>Registration desk open</p>	
08:00-09:00	<p>Industry Symposium 7 📍 PAC</p>	<p>Industry Symposium 8 📍 Exhibit Hall A1</p>
09:30-11:00	<p>📍 PAC</p> <p>Topic 2: Pathobiology of neuromuscular expansion disorders 1 <i>Moderators: Ichizo Nishino, National Institute of Neuroscience, NCNP, Japan & Louise Benarroch, Centre De Recherche En Myologie, France</i></p> <p>09:30-10:00 INV08: RAN translation in C9orf72 ALS/FTD and other repeat opportunities <i>Laura Ranum, University of Florida, USA</i></p> <p>10:00-10:30 INV09: Novel repeat disorders in muscle disease: the emergence of OPDM <i>Zhaoxia Wang, Peking University First Hospital, China</i></p> <p>10:30-10:45 O07: RAN translation of expanded CGG repeat in LRP12 may contribute to oculopharyngodistal myopathy, <i>Chengcheng Li, Washington University in St. Louis, USA</i></p> <p>10:45-11:00 O08: Single-nucleus RNA sequencing reveals characteristic gene expression in pathologically-specific myofibers in oculopharyngodistal myopathy <i>Nobuyuki Eura, Nara Medical University, Japan</i></p>	



11:00-11:30	Morning refreshments & exhibition 📍 Exhibit Hall and posters 📍 Ballroom
11:00-11:30	Guidelines Committee find out about how to get involved 📍 Myology Café, Exhibit Hall
11:30-13:30	<p>📍 PAC Topic 2: Pathobiology of neuromuscular expansion disorders 2 <i>Moderators: Gauthier Remiche, Hopital Erasme, Belgium & Nicol Voermans, Radboud University Medical Center, The Netherlands</i></p> <p>11:30-12:00 INV10: Genetic discovery and pathomechanism of repeat disorders in neuromuscular diseases: lessons from RFC1 <i>Henry Houlden, UCL Queen Square, Institute of Neurology, UK</i></p> <p>12:00-12:30 INV11: Motor neuron and muscle involvement in SBMA: therapeutic implications <i>Kenneth Fischbeck, National Institutes of Health (NIH), USA</i></p> <p>12:30-12:45 O09: Bi-allelic variants of FILIP1 cause congenital myopathy, dysmorphism and neurological defects <i>Andreas Roos, University Medicine Essen, Germany</i></p> <p>12:45-13:00 O10: Universal genomic newborn screening for early, treatable, and severe conditions- including 33 genes of NMD: Baby Detect <i>Tamara Dangouloff, University Of Liege, Belgium</i></p> <p>13:00-13:15 O11: Long-read nanopore sequencing in FSHD patients reveals CpG methylation patterns including methylation gradients in contracted D4Z4 arrays <i>Russell Butterfield, University of Utah, USA</i></p> <p>13:15-13:30 O12: Muscle imaging in natural history of FSHD: quantitative MRI and ultrasound results compared head-to-head <i>Sanne Vincenten, Radboudumc, The Netherlands</i></p>
13:30-14:45	Lunch & exhibition 📍 Exhibit Hall and posters 📍 Ballroom
13:45-14:45	<p>Career Development Workshop 📍 Ballroom C1 (Lunch available in the room) <i>Moderator: Chris Weihl, Washington University in St. Louis, USA</i> <i>Panel: Meredith James, John Walton, Muscular Dystrophy Research Centre, UK, Mike Lawlor, Medical College of Wisconsin, USA, Coen Ottenheijm, Amsterdam UMC, The Netherlands and Carmen Paradas, Hospital Virgen del Rocío, Spain</i></p>
14:45-18:00	Poster viewing / Group Activity (separate registration required)
18:00-21:00	Group Activity Reception (separate registration required)

Friday 6th October 2023

06:45-18:00	Registration desk open
07:30-08:30	<p>Interesting Case Discussions 📍 PAC (Refreshments available) <i>Cases presented by delegates</i> <i>Moderators: Reghan Foley, National Institute of Health, USA and Riyad El-Khoury, Genethon, France</i></p>
08:30-08:45	Comfort break
08:45-10:00	<p>📍 PAC Topic 3: The effect of lifestyle, exercise and nutrition on neuromuscular pathology and outcomes 1 <i>Moderators: Salman Bhai, UT Southwestern, USA & Jean-Yves Hogrel, Association Institut de Myologie, France</i></p>



	<p>08:45-09:15 INV12: The exposome in neuromuscular disorders <i>Eva Feldman, The University of Michigan, USA</i></p> <p>09:15-09:45 INV13: Development of a cycle training paradigm to improve exercise capacity and pathophysiology in boys with Duchenne muscular dystrophy, <i>Tanja Taivassalo, University of Florida, USA</i></p> <p>09:45-10:00 O13: Promoting an active lifestyle; use of an in-home body weight support system to increase exercise dosage for children with neuromuscular disease <i>Megan Iammarino, Nationwide Children's Hospital, USA</i></p>
10:00-10:30	Morning refreshments & exhibition 📍 Exhibit Hall and posters 📍 Ballroom
10:00-10:30	Myology Developments Across the World and Education Committees find out about how to get involved 📍 Myology Café, Exhibit Hall
10:30-12:00	<p>📍 PAC</p> <p>Topic 3: The effect of lifestyle, exercise and nutrition on neuromuscular pathology and outcomes 2 <i>Moderators: Linda Lowes, Nationwide Children's Hospital, USA & John Vissing, Rigshospitalet, Denmark</i></p> <p>10:30-11:00 INV14: Physical activity and exercise are more than medicine for neuromuscular disorders <i>Nicole Voet, Radboud University Medical Centre, The Netherlands</i></p> <p>11:00-11:15 O14: Experiences with pregnancy and pregnancy-related physiotherapy in women with Charcot-Marie-Tooth disease. A qualitative interview study <i>Andreas Rosenberger, National Neuromuscular Centre, Norway</i></p> <p>11:15-11:30 O15: Large-scale proteomics profiling of peripheral blood of DM1 patients identifies biomarkers for disease severity and physical activity <i>Peter-Bram 't Hoen, Radboud University Medical Center, The Netherlands</i></p> <p>11:30-11:45 O16: New FDX2-loss of function phenotype presenting with blindness and myopathy with potential responsiveness to Co-enzyme Q10 analogs <i>Reghan Foley, National Institute of Health, USA</i></p> <p>11:45-12:00 O17: 6'-sialyllactose supplementation in GNE myopathy: a pilot and subsequent placebo-controlled study <i>Young-eun Park, Pusan National University Hospital, South Korea</i></p>
12:15-13:15	WMS General Assembly/Poster viewing for non-members 📍 Exhibit Hall A1
13:00-14:00	Lunch & exhibition 📍 Exhibit Hall and posters 📍 Ballroom
13:30-14:00	Sponsor Meeting 📍 Meeting Room 10
14:00-15:00	<p>Poster session 3 📍 Ballroom A-C <i>Refreshments served</i></p> <p>P68-P70, VP71, P72-P81: SMA - outcome measures P152-P162, VP163, P164-P166, VP167: Distal myopathies P191-P204: Registries P252-P258, VP259, P260, P262-P268: Dystrophinopathies P368, VP369, P370-P380, VP381, P382: Pompe disease</p>



	<p>P383-P395, VP396, P397: Myotonic dystrophy</p> <p>P421-P426, VP427, P428, VP429, P430-P434, VP435-436: Congenital muscular dystrophies</p>		
15:00- 15:30	<p>Short Oral Presentations 7</p> <p>📍 Ballroom C1</p> <p>P152-157</p> <p>Moderator: <i>Bjarne Udd, Tampere Neuromuscular Center, Finland</i></p>	<p>Short Oral Presentations 8</p> <p>Ballroom C2</p> <p>📍 P158, P421-424</p> <p>Moderator: <i>Payam Mohassel, Johns Hopkins University, USA</i></p>	<p>Short Oral Presentations 9</p> <p>📍 Ballroom C3</p> <p>P159, P368, P383-384, P191-192</p> <p>Moderator: <i>Carolina Tesi Rocha, Stanford University, USA</i></p>
15:30-16:30	<p>Poster session 4 📍 Ballroom A-C Refreshments served</p>		
	<p>P01-P05, VP06-VP07, P08-P11: SMA - therapies</p> <p>P82-P113: Outcome measures</p> <p>P235-P250: DMD - clinical care and cases</p> <p>VP270, P271-P273, VP274, P275-P278, VP279, P280: Myasthenia gravis</p> <p>VP341, P342, VP343, P344-P348, VP349, P350-P356, VP357, P358-P367: Metabolic and mitochondrial myopathies</p> <p>P437-P446, VP447, P448: Motor neuron disease and neuropathies</p> <p>LBP01-LBP21, LBVP01-LBVP03: Late Breaking</p>		
16:30-16:45	<p>Short Oral Presentations 10</p> <p>📍 Ballroom C1</p> <p>P82-P87</p> <p>Moderator: <i>Tina Duong, Stanford University, USA</i></p>	<p>Short Oral Presentations 11</p> <p>📍 Ballroom C2</p> <p>P235, P01-P02</p> <p>Moderator: <i>Jorge Alfredo Bevilacqua, Universidad de Chile & Clínica Dávila, Chile</i></p>	
18:00-18:30	Transport to Networking Pre-Dinner Drinks (separate registration required)		
18:30-19:30	Pre-Networking Dinner Drinks 📍 Sharehouse, Downtown Charleston (separate registration required)		
19:30-23:00	Networking Dinner 📍 The Bus Shed, Downtown Charleston (separate registration required)		

Saturday 7th October 2023

07:30-15:00	Registration desk open
07:30-09:00	Arrival refreshments 📍 PAC Foyer
07:45-08:45	<p>Clinical Trial Updates 📍 PAC</p> <p>Moderators: <i>Kristl Claeys, Universitaire Ziekenhuizen Leuven, Belgium & Ulrike Schara Schmidt, University of Essen, Germany</i></p> <p>O18: Topline Safety and Efficacy Data Analysis of Phase 1/2 Clinical Trial Evaluating AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA™ <i>Nicholas Johnson, Virginia Commonwealth University, USA</i></p> <p>O19: Preliminary Results from MLB-01-003: An Open Label Phase 2 Study of BBP-418 in Patients with Limb-girdle Muscular Dystrophy Type 2I/R9 <i>Amy Harper, Virginia Commonwealth University, USA</i></p> <p>O20: Safety and efficacy of intravenous onasemnogene abeparvovec in patients with spinal muscular atrophy: interim findings from the phase 3 SMART study <i>Hugh McMillan, Children's Hospital of Eastern Ontario, USA</i></p> <p>O21: 104-week efficacy and safety of cipaglucosidase alfa+miglustat in patients with late-onset Pompe disease previously treated with alglucosidase alfa <i>Tahseen Mozaffar, University of California, USA</i></p>



09:00-11:00

The Victor Dubowitz Lecture 📍 PAC

Moderators: Volker Straub, Newcastle University, UK & Chris Weihl, Washington University in St. Louis, USA

09:00-09:30 **INV15 RNA-targeted therapy for ALS**

Tim Miller, Washington University, USA

Poster Highlights 📍 PAC

Moderators: Alan Beggs, Boston Childrens Hospital / Harvard Medical School, USA & Svetlana Gorokhova, National Institute of Health, USA

O22: P81 Gastrointestinal assessment in Spinal Muscular Atrophy (SMA): the experience of SMA healthcare professionals in France

Marta Gomez Garcia, APHP Raymond Poincare University Hospital, Child Neurology and Paediatric ICU Department Pediatrique, France

O23: P161 Natural history of distal and myofibrillar myopathies assessed by clinical and technological outcome measures (Dista-Myo): baseline results

Giorgio Tasca, Newcastle University, UK

O24: P266 Gene expression profiles and spatial localisation of dystrophin isoforms in developing and adult human brain

Francesco Catapano, University College London, UK

O25: P325 A comparative single nuclei transcriptomics approach to evaluating the terminally differentiated lymphocytes in autoimmune Myositis

Francia Victoria De Los Reyes, National Center of Neurology and Psychiatry (NCNP), Japan

O26: P350 Clinical characteristics and therapeutic response of patients with adult-onset Multiple Acyl-CoA-Dehydrogenase Deficiency (MADD)

Sofie Sunebo, Linköping University Hospital, Sweden

O27: P425 Inhibition of TGF β signaling pathway as a therapeutic approach in collagen VI-related muscular dystrophy

Hailey Hearn, Johns Hopkins University, USA

11:00-11:30

Morning refreshments 📍 PAC Foyer **and posters** 📍 Ballroom

11:30-13:30

Late Breaking News 📍 PAC

Moderator: Lindsay Wallace, Nationwide Children's Hospital, USA and Michele Yang, Children's Hospital Colorado, USA

LBO01: Impaired iron-sulfur cluster assembly due to biallelic variants in CIAO1 leads to a novel muscle disease
Rotem Or Bach, National Institute of Health, USA

LBO02: Ablation of the Carboxiterminal end of MAMDC2 causes a distinct muscular dystrophy
Carmen, Paradas, Hospital Virgen del Rocío, Spain

LBO03: A novel class of Tubulinopathies - Mutations in TUBA4A cause primary skeletal muscle disorders
Mridul Johari, Harry Perkins Institute of Medical Research - UWA, Australia

LBO04: CGG repeat expansion in LRP12 causes both amyotrophic lateral sclerosis and oculopharyngodistal myopathy type 1
Takashi Kurashige, Nho Kure Medical Center and Chugoku Cancer Center, Japan

LBO05: Proteomic serum profiling identifies ITIH3 as a new biomarker for Myasthenia gravis disease activity
Tobias Ruck, Heinrich Heine University Düsseldorf, Germany

LBO06: Functional improvements and decreased aggregate burden in TgT571 Mice following AAVrh74.tMCK.hBAG3 gene therapy
Burcak Ozes, Nationwide Children's Hospital, USA

LBO07: RNA-based CRISPRoff silencing to target DUX4 in Facioscapulohumeral muscular dystrophy
Junjie He, Center For iPS Cell Research And Application (CiRA), Kyoto University, Japan

LBO08: Identification of AAV variants with enhanced skeletal muscle and muscle stem cell transduction
Melissa Spencer, UCLA David Geffen School of Medicine, USA

LBO09: scAAV9.U7-ACCA treatment of DMD exon 2 duplication leads to significant dystrophin expression and evidence of clinical benefit, particularly following treatment as an infant
Kevin Flanigan, The Research Institute at Nationwide Children's Hospital, USA

Prize Giving Ceremony 📍 PAC

Moderator: Johann Böhm

Introduction to the WMS 2024 Congress, Prague, Czech Republic

Jana Haberlová

Handover of the WMS flag and close of congress

Moderator: Volker Straub

13:30-14:30

Homeward lunch 📍 PAC Foyer

13:30-15:00

NMD Board Meeting 📍 Meeting room 6 & 7 (separate registration required)